PAVmed Inc. (Nasdaq: PAVM), a commercial-stage medical technology company, has announced a strategic partnership with The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James). This collaboration follows the successful completion of a pilot program utilizing the Veris Cancer Care Platform™. The partnership entails a long-term, multi-project agreement aimed at expanding the commercial use of the platform across various cancer care service lines, integrating it with electronic health records, and developing a large clinical registry. Additionally, a clinical trial for an implantable physiological monitor, pending FDA clearance, is set to launch next year. This initiative is part of the company's efforts to enhance cancer care through innovative digital health solutions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.